Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYANNASDAQ:KODNASDAQ:ORPHNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYANCyanotech$0.41+14.0%$3.01$2.37▼$6.29$2.94M-0.113,483 shs200 shsKODKodiak Sciences$3.86+3.9%$3.84$1.92▼$11.60$202.60M2.28344,408 shs5,651 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsPHARPharming Group$10.51+6.3%$10.46$6.65▼$12.61$714.66M0.026,097 shs379 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYANCyanotech0.00%-10.00%-10.00%+17.88%-9.73%KODKodiak Sciences-6.31%-0.54%-12.09%+80.10%+57.87%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%PHARPharming Group+0.87%-1.93%-12.32%+33.55%+28.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYANCyanotechN/AN/AN/AN/AN/AN/AN/AN/AKODKodiak Sciences4.1206 of 5 stars3.04.00.04.61.13.30.0ORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/APHARPharming Group2.733 of 5 stars3.55.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYANCyanotech 0.00N/AN/AN/AKODKodiak Sciences 2.00Hold$9.00133.46% UpsideORPHOrphazyme A/S 0.00N/AN/AN/APHARPharming Group 3.00Buy$30.00185.58% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYANCyanotech$23.07M0.13N/AN/A$1.33 per share0.31KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/AORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/APHARPharming Group$297.20M2.40$0.07 per share142.73$3.25 per share3.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYANCyanotech-$5.27M-$0.66N/A∞N/A-19.50%-44.71%-19.12%N/AKODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/APHARPharming Group-$11.84M-$0.20N/A350.17N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)Latest CYAN, PHAR, KOD, and ORPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYANCyanotechN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYANCyanotech0.111.060.28KODKodiak SciencesN/A4.624.62ORPHOrphazyme A/S0.141.80N/APHARPharming Group0.392.762.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYANCyanotech24.40%KODKodiak Sciences89.06%ORPHOrphazyme A/S10.74%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipCYANCyanotech29.10%KODKodiak Sciences45.90%ORPHOrphazyme A/SN/APHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYANCyanotech957.16 million5.07 millionNot OptionableKODKodiak Sciences9052.76 million28.55 millionOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionablePHARPharming Group28068.03 million66.62 millionNot OptionableCYAN, PHAR, KOD, and ORPH HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Shares Gap Down - What's Next?July 3, 2025 | marketbeat.comAS:PHAR Financials | Pharming Group NV - Investing.comJuly 2, 2025 | investing.comPharming Group (NASDAQ:PHAR) Stock Price Down 4.9% - Here's What HappenedJuly 1, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Here's WhyJune 30, 2025 | marketbeat.comPharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS ...June 25, 2025 | morningstar.comMPharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve ... - NasdaqJune 25, 2025 | nasdaq.comPharming Group (NASDAQ:PHAR) Shares Down 3.2% - Here's WhyJune 18, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's What HappenedJune 17, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?June 16, 2025 | marketbeat.comShort Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%June 13, 2025 | marketbeat.comEuropean Penny Stocks Under €200M Market Cap To WatchJune 13, 2025 | uk.finance.yahoo.comPharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What HappenedJune 12, 2025 | marketbeat.comPharming Group reports on results of the 2025 Annual General Meeting of ShareholdersJune 11, 2025 | finance.yahoo.comPharming Group Announces Key Board Appointments and Approvals at 2025 AGMJune 11, 2025 | tipranks.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's WhyJune 11, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What HappenedJune 10, 2025 | marketbeat.comPharming Group to participate in June investor conferencesMay 28, 2025 | finance.yahoo.comPharming Group to participate in June investor conferences | PHARM Stock NewsMay 28, 2025 | gurufocus.comPharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)May 10, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comPharming Group N.V. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsCYAN, PHAR, KOD, and ORPH Company DescriptionsCyanotech NASDAQ:CYANCyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.Kodiak Sciences NASDAQ:KOD$3.86 +0.15 (+3.91%) As of 10:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Pharming Group NASDAQ:PHAR$10.50 +0.63 (+6.33%) As of 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
